{"id":11389,"date":"2022-02-08T06:42:13","date_gmt":"2022-02-08T12:42:13","guid":{"rendered":"https:\/\/leukemiarf.org\/?p=11389"},"modified":"2022-07-27T09:26:31","modified_gmt":"2022-07-27T14:26:31","slug":"discovery-broadens-car-t-cell-therapy","status":"publish","type":"post","link":"https:\/\/leukemiarf.org\/news\/discovery-broadens-car-t-cell-therapy\/","title":{"rendered":"Discovery Broadens Applications for CAR T-Cell Therapy"},"content":{"rendered":"\n
CAR T-cell therapy uses a patient\u2019s modified T cells to target their cancer. This therapy takes advantage of what T-cells do naturally \u2013 find and destroy invaders.<\/p>\n\n\n\n
While CAR T-cell therapy has been a game-changer, it is not effective at treating all types of cancer. In some cases, the engineered T cells become exhausted and stop fighting. The therapy is also less effective against solid tumors.<\/p>\n\n\n\n
Researchers at Children\u2019s Hospital of Los Angeles are investigating ways to broaden the applications for CAR T-cell therapy in leukemia patients. In preliminary studies, they have found that increasing the activity of a gene found in T cells makes them stronger and longer-lasting. This gene is called BCL11B.<\/p>\n\n\n\n
Chintan Parekh, MD, a physician-scientist in the Cancer and Blood Disease Institute at Children\u2019s Hospital Los Angeles, is leading the study.<\/p>\n\n\n\n
\u201cSo far, in our experiments, these modified T cells are working harder,\u201d he says. \u201cThey don\u2019t exhaust or die off as easily. They stay in the fight longer. This could eventually translate into more effective therapies for patients with resistant leukemia or solid tumors.\u201d<\/p>\n\n\n\n
But the potential applications don\u2019t end there. The researchers also found that this same gene instructs developing immune cells to become T cells. This means that increasing the gene in developing immune cells could encourage T cell regrowth in patients.<\/p>\n\n\n\n